1. Home
  2. NFGC vs FTRE Comparison

NFGC vs FTRE Comparison

Compare NFGC & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Found Gold Corp

NFGC

New Found Gold Corp

HOLD

Current Price

$2.03

Market Cap

928.8M

ML Signal

HOLD

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$13.66

Market Cap

829.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NFGC
FTRE
Founded
2016
1996
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
928.8M
829.3M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
NFGC
FTRE
Price
$2.03
$13.66
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$14.06
AVG Volume (30 Days)
1.7M
1.5M
Earning Date
05-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,723,400,000.00
Revenue This Year
$3,542.00
N/A
Revenue Next Year
$118.57
$3.09
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.00
52 Week Low
$1.19
$3.97
52 Week High
$3.59
$18.67

Technical Indicators

Market Signals
Indicator
NFGC
FTRE
Relative Strength Index (RSI) 44.96 59.26
Support Level $1.85 $8.85
Resistance Level $2.14 $18.26
Average True Range (ATR) 0.14 0.82
MACD 0.01 0.07
Stochastic Oscillator 36.47 54.77

Price Performance

Historical Comparison
NFGC
FTRE

About NFGC New Found Gold Corp

New Found Gold Corp is a mineral exploration company engaged in the acquisition, exploration and evaluation of resource properties with a focus on gold properties located in the Provinces of Newfoundland and Labrador and Ontario, Canada. The Company's exploration is focused on discovering and delineating gold resources. The Company has one material property: the Queensway Project located in Newfoundland, Canada (the Queensway Project).

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Share on Social Networks: